Replimune Group (NASDAQ:REPL) Shares Gap Up – Time to Buy?

Shares of Replimune Group, Inc. (NASDAQ:REPL) gapped up before the market opened on Tuesday . The stock had previously closed at $13.26, but opened at $13.64. Replimune Group shares last traded at $14.15, with a volume of 561,791 shares changing hands.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. BMO Capital Markets boosted their target price on Replimune Group from $14.00 to $18.00 and gave the stock an “outperform” rating in a report on Friday. JPMorgan Chase & Co. lifted their target price on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, September 24th. HC Wainwright reiterated a “buy” rating and issued a $17.00 price target on shares of Replimune Group in a report on Friday. Roth Capital upgraded Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. Finally, Roth Mkm assumed coverage on Replimune Group in a research note on Tuesday, August 27th. They issued a “buy” rating and a $17.00 target price for the company. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Replimune Group presently has a consensus rating of “Buy” and an average target price of $17.00.

Replimune Group Price Performance

The business’s 50-day moving average price is $11.64 and its two-hundred day moving average price is $9.81. The firm has a market cap of $960.62 million, a price-to-earnings ratio of -4.37 and a beta of 1.19. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.07. On average, research analysts forecast that Replimune Group, Inc. will post -3.02 EPS for the current fiscal year.

Insider Buying and Selling

In other Replimune Group news, insider Konstantinos Xynos sold 7,246 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the sale, the insider now owns 109,885 shares in the company, valued at approximately $1,184,560.30. This trade represents a 6.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 8.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Baker BROS. Advisors LP raised its holdings in shares of Replimune Group by 10.0% in the 3rd quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock worth $121,057,000 after purchasing an additional 1,000,000 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in Replimune Group by 12.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company’s stock worth $53,505,000 after acquiring an additional 699,679 shares during the period. Millennium Management LLC grew its holdings in shares of Replimune Group by 575.1% during the 2nd quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock valued at $28,062,000 after acquiring an additional 2,656,173 shares in the last quarter. Braidwell LP increased its holdings in Replimune Group by 203.0% in the third quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock worth $33,656,000 after buying an additional 2,057,460 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of Replimune Group by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 2,770,328 shares of the company’s stock worth $22,634,000 after purchasing an additional 32,555 shares during the last quarter. 92.53% of the stock is owned by institutional investors and hedge funds.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.